Attributes | Values |
---|
rdf:type
| |
Description
| - Sitagliptin je perorální antidiabetikum, využivajici učinky inkretinovych hormonů. Jedna se o specificky inhibitor enzymu DPP-4 (dipeptidyl peptidase-4), ktery ovlivňuje degradaci a aktivitu inkretinovych hormonů, GLP-1 (glucagon-like peptide ? 1) a GIP (glucose-dependent insulinotropic polypeptide). Sitagliptin je charakterizovan velmi malym rizikem hypoglykemii v průběhu lečby, redukuje HbA1C, neovlivňuje tělesnou hmotnost a je velmi dobře snášen. Nejvice je využivan v kombinačni lečbě s metforminem a glitazony. V experimentalnich studiich inhibuje apoptozu a stimuluje proliferaci beta-buněk pankreatu, což vede k narůstu jejich množstvi.
- Sitagliptin je perorální antidiabetikum, využivajici učinky inkretinovych hormonů. Jedna se o specificky inhibitor enzymu DPP-4 (dipeptidyl peptidase-4), ktery ovlivňuje degradaci a aktivitu inkretinovych hormonů, GLP-1 (glucagon-like peptide ? 1) a GIP (glucose-dependent insulinotropic polypeptide). Sitagliptin je charakterizovan velmi malym rizikem hypoglykemii v průběhu lečby, redukuje HbA1C, neovlivňuje tělesnou hmotnost a je velmi dobře snášen. Nejvice je využivan v kombinačni lečbě s metforminem a glitazony. V experimentalnich studiich inhibuje apoptozu a stimuluje proliferaci beta-buněk pankreatu, což vede k narůstu jejich množstvi. (cs)
- Sitagliptin is an oral antidiabetic incretin-based drug. It is a specific inhibitor of DPP-4 (dipeptidyl peptidase-4), which regulates the degradation and the bioactivity of native GLP-1 (glucagon-like peptide ? 1) and GIP (glucose-dependent insulinotropic polypeptide). Sitagliptin is characterized by low incidence of hypoglycemia during the therapy. Sitagliptin reduces mean HbA1c and has a neutral inpact on body weight. Sitagliptin is generally well tolerated, with no significant side effects. Sitagliptin is being used in combination with metformin and thiazonlidindiones. In experimental studies sitagliptin inhibits apoptosis of islets beta-cells and stimulates their proliferation, which results in increasing of beta-cell mass. (en)
|
Title
| - Sitagliptin (en)
- Sitagliptin (cs)
- Sitagliptin
|
skos:prefLabel
| - Sitagliptin (en)
- Sitagliptin (cs)
- Sitagliptin
|
skos:notation
| - RIV/61989592:15110/09:10223534!RIV12-MSM-15110___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/09:10223534
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - type 2 diabetes mellitus; GIP; GLP-1; incretin hormones; DPP-4 inhibitors; sitagliptin (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - Klinická farmakologie a farmacie
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| |
issn
| |
number of pages
| |
http://localhost/t...ganizacniJednotka
| |